Tags

Type your tag names separated by a space and hit enter

Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome.
Mod Rheumatol 2019; :1-6MR

Abstract

OBJECTIVES

The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS).

METHODS

This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group).

RESULTS

After excluding 11 miscarriages with abnormal embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates of patients treated with danaparoid and UFH were similar and tended to be higher than that of patients treated with LDA, respectively (OR 4.0, 95% confidence interval 0.72-22.22 and 5.15, 1.33-20.00). No patient given danaparoid and one patient with UFH developed heparin-induced thrombocytopenia which resulted in a stillbirth. Another patient with UFH suffered a lumbar compression fracture.

CONCLUSION

Danaparoid is effective for improving the live birth rate and is safe for patients with oAPS.

Authors+Show Affiliations

a Department of Obstetrics and Gynecology , Nagoya City University, Graduate School of Medical Sciences , Nagoya , Japan.a Department of Obstetrics and Gynecology , Nagoya City University, Graduate School of Medical Sciences , Nagoya , Japan.a Department of Obstetrics and Gynecology , Nagoya City University, Graduate School of Medical Sciences , Nagoya , Japan.b Obstetrics & Gynecology Katano Clinic , Kasugai , Japan.a Department of Obstetrics and Gynecology , Nagoya City University, Graduate School of Medical Sciences , Nagoya , Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30924705

Citation

Yoshihara, Hiroyuki, et al. "Danaparoid Is Effective and Safe for Patients With Obstetric Antiphospholipid Syndrome." Modern Rheumatology, 2019, pp. 1-6.
Yoshihara H, Sugiura-Ogasawara M, Kitaori T, et al. Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome. Mod Rheumatol. 2019.
Yoshihara, H., Sugiura-Ogasawara, M., Kitaori, T., Katano, K., & Ozaki, Y. (2019). Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome. Modern Rheumatology, pp. 1-6. doi:10.1080/14397595.2019.1602241.
Yoshihara H, et al. Danaparoid Is Effective and Safe for Patients With Obstetric Antiphospholipid Syndrome. Mod Rheumatol. 2019 Mar 29;1-6. PubMed PMID: 30924705.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Danaparoid is effective and safe for patients with obstetric antiphospholipid syndrome. AU - Yoshihara,Hiroyuki, AU - Sugiura-Ogasawara,Mayumi, AU - Kitaori,Tamao, AU - Katano,Kinue, AU - Ozaki,Yasuhiko, Y1 - 2019/03/29/ PY - 2019/3/30/pubmed PY - 2019/3/30/medline PY - 2019/3/30/entrez KW - Antiphospholipid syndrome KW - danaparoid KW - lupus anticoagulant KW - recurrent miscarriage KW - recurrent pregnancy loss SP - 1 EP - 6 JF - Modern rheumatology JO - Mod Rheumatol N2 - OBJECTIVES: The objective is to evaluate whether danaparoid is effective in improving the live birth rate in patients with obstetric antiphospholipid syndrome (oAPS). METHODS: This prospective study included 91 pregnancies of 60 patients with oAPS diagnosed according to criteria of the International Congress on APS. Live birth rates, adverse pregnancies and perinatal outcomes were compared among patients treated with danaparoid and low dose aspirin (danaparoid group, LDA), unfractionated heparin (UFH) and LDA (UFH group) and LDA and/or prednisolone (LDA group). RESULTS: After excluding 11 miscarriages with abnormal embryonic chromosomes, one chemical pregnancy and one ectopic pregnancy, live birth rates were 87.5% (14/16) for the danaparoid group, 90.0% (36/40) for the UFH group and 63.6% (14/22) for the LDA group, respectively. The live birth rates of patients treated with danaparoid and UFH were similar and tended to be higher than that of patients treated with LDA, respectively (OR 4.0, 95% confidence interval 0.72-22.22 and 5.15, 1.33-20.00). No patient given danaparoid and one patient with UFH developed heparin-induced thrombocytopenia which resulted in a stillbirth. Another patient with UFH suffered a lumbar compression fracture. CONCLUSION: Danaparoid is effective for improving the live birth rate and is safe for patients with oAPS. SN - 1439-7609 UR - https://www.unboundmedicine.com/medline/citation/30924705/Danaparoid_is_effective_and_safe_for_patients_with_obstetric_antiphospholipid_syndrome L2 - http://www.tandfonline.com/doi/full/10.1080/14397595.2019.1602241 DB - PRIME DP - Unbound Medicine ER -